Not yet recruitingPhase 1NCT06567080
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- RenJi Hospital
- Principal Investigator
- Liangjing LuRenJi Hospital
- Intervention
- JWCAR201(biological)
- Enrollment
- 15 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Collaborators
Shanghai Ming Ju Biotechnology Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06567080 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGEARLY PHASE1NCT07339332A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus ErythematosusUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT07109986UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus NephritisNanjing IASO Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGNANCT07196072A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic PainUniversity of Michigan
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGNCT06659029Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersAstraZeneca
- RECRUITINGPHASE1NCT06613360A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusCullinan Therapeutics Inc.
- RECRUITINGNCT07017868Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis PatientsSohag University